A Clinical Study of Ultrasound-guided Botulinum Toxin A Into Salivary Gland for Sialorrhea After True Bulbar Palsy

NCT ID: NCT07070817

Last Updated: 2025-07-17

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-01
• Study Completion Date: 2025-09-01

Brief Summary

Sialorrhea refers to a group of syndromes characterized by excessive saliva secretion from the salivary glands or reduced clearance of oral saliva due to dysphagia, resulting in saliva overflowing from the corners of the mouth or accumulating in the pharynx. It is one of the common clinical problems in conditions such as cerebral palsy, Parkinson's disease [1], and brain injuries (including stroke, traumatic brain injury, and hypoxic-ischemic encephalopathy). Among them, true bulbar palsy after medullary injury often causes saliva to flow out from the corners of the mouth due to sensory impairment in the oral cavity, tongue, and pharynx, as well as motor dysfunction and loss of coordination of swallowing-related muscles [2]; on the other hand, it often leads to residual saliva in the hypopharynx due to weakness of the pharyngeal constrictor muscles and dysfunction of the upper esophageal sphincter [3]. Sialorrhea can not only cause oral odor, skin breakdown, and malnutrition but also have a negative impact on patients' psychology, and even lead to choking or aspiration pneumonia, seriously endangering their physical and mental health. Therefore, active management and treatment of sialorrhea in patients with true bulbar palsy have become the key to solving this problem.

Currently, the management of sialorrhea mainly involves improving swallowing function to enhance saliva clearance and using drug intervention to reduce saliva secretion, thereby alleviating sialorrhea symptoms. However, current studies have found that swallowing function cannot recover quickly in a short time in patients with medullary injury. Therefore, active intervention is needed to reduce saliva secretion to relieve sialorrhea symptoms. Clinical treatments for sialorrhea include drug therapy, botulinum toxin therapy, radiation therapy, and surgical treatment. Among them, oral drug therapy is mainly based on antimuscarinic drugs. Although it has a certain therapeutic effect, its clinical application is limited due to the side effects of systemic anticholinergic effects; while surgical treatment is not clinically adopted because of its high destructiveness.

In recent years, a number of clinical studies on botulinum toxin type A (BTX-A) in the treatment of sialorrhea in adults (Parkinson's disease, traumatic brain injury) and children (cerebral palsy) have been carried out at home and abroad, and its efficacy and safety have been verified [4] [5]. However, there are few reports on BTX-A in the treatment of sialorrhea in patients with medullary lesions. Therefore, this study aims to conduct a randomized controlled trial to explore the effect of ultrasound-guided botulinum toxin type A injection into the salivary glands on sialorrhea in patients with true bulbar palsy, and comprehensively evaluate the efficacy and safety of BTX-A in the treatment of sialorrhea by combining subjective scale assessment and objective instrument assessment.

Conditions

Sialorrhea True Bulbar Palsy Medullary Injury

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection Group

Experimental Arm (Group B) Intervention: Participants receive ultrasound-guided A 100IU (BTX-A) injection into the salivary glands combined with the same routine swallowing rehabilitation training as the control arm.

Details of BTX-A injection:

BTX-A is diluted with 2 mL of 0.9% NaCl. Injections are administered under ultrasound guidance, targeting the parotid and submandibular glands (specific dosage and injection sites follow clinical standards).

Rehabilitation training: Identical in content, frequency, and duration to the control arm, ensuring that any differences in outcomes can be attributed to the BTX-A injection.

Group Type: EXPERIMENTAL

Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection

Intervention Type: DRUG

Ultrasound-guided injection of BoNT-A (specific dosage, e.g., "100 units") into target salivary glands ( parotid and submandibular glands) at baseline.

Ultrasound-Guided Saline (Placebo) Salivary Gland Injection Group

Description: This arm includes participants with true bulbar palsy and sialorrhea who will receive ultrasound-guided injections of a placebo (sterile saline) into the salivary glands. It serves as a control to compare against the active intervention arm.

Group Type: PLACEBO_COMPARATOR

Control (Normal saline)

Intervention Type: DRUG

Intervention: Participants receive routine swallowing rehabilitation training only.

Details of training: The training includes standard techniques to improve swallowing function, such as oral motor training, empty swallowing exercises, and ice stimulation. The frequency and duration of training are consistent across all participants in this arm to ensure standardization.

Interventions

Ultrasound-Guided Botulinum Toxin Type A (BoNT-A) Salivary Gland Injection

Ultrasound-guided injection of BoNT-A (specific dosage, e.g., "100 units") into target salivary glands ( parotid and submandibular glands) at baseline.

Intervention Type: DRUG

Control (Normal saline)

Intervention: Participants receive routine swallowing rehabilitation training only.

Details of training: The training includes standard techniques to improve swallowing function, such as oral motor training, empty swallowing exercises, and ice stimulation. The frequency and duration of training are consistent across all participants in this arm to ensure standardization.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

-

Exclusion Criteria

• Having an allergy or contraindication to botulinum toxin;

• Having taken drugs for treating sialorrhea or drugs that can cause sialorrhea in the recent month;

• Having severe diseases of important organs such as the heart, lungs, liver, kidneys, or malignant tumors, etc.; ⑤ Concomitantly using aminoglycoside antibiotics and warfarin; ⑥ Patients with infection or skin lesions at the injection site, or severe muscle atrophy at the injection site, or those with infection at the injection site, or skin lesions at the injection site, or severe muscle atrophy at the injection site, or infection.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

houyajing

OTHER

Sponsor Role: lead

Responsible Party

houyajing

Fuxing Hospital affiliated to Capital Medical University

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Fuxing Hospital Affiliated to Capital Medical University

Beijing, , China

Countries

China

Other Identifiers

2024FXHEC-KSP017

Identifier Type: -

Identifier Source: org_study_id